Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion.
malignant pleural effusion
non-small cell lung cancer
overall survival
prognostic score
Journal
The clinical respiratory journal
ISSN: 1752-699X
Titre abrégé: Clin Respir J
Pays: England
ID NLM: 101315570
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
30
08
2023
received:
03
06
2023
accepted:
03
09
2023
medline:
10
11
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
ppublish
Résumé
Patients with malignant pleural effusion (MPE) typically have poor prognoses, and predicting survival is challenging. The present study aimed to identify prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients with MPE in the time of immunotherapy and targeted therapy. Data of 344 consecutive NSCLC patients with MPE on clinical, radiological, and molecular characteristics and treatment options were collected. The risk factors in the training cohort were assessed using univariate and multivariate proportional hazards analyses. A clinical prognostic score was established and validated. According to the results of the multivariable survival analysis, the Eastern Cooperative Oncology Group (ECOG) performance score (PS), antiangiogenic therapy, immunotherapy, and lactic dehydrogenase (LDH) in pleural fluid (CAIL) prognostic score was developed (n = 275) and subsequently validated (n = 69). Patients who underwent risk stratification into low-, moderate-, and high-risk groups had median OS of 46.1, 23.1, and 9.6 months, respectively (P < 0.0001). The area under the curve (AUC) analysis showed the CAIL score to be superior at predicting survival compared with the LENT score at 6 (0.84 vs. 0.77, P < 0.01), 12 (0.87 vs. 0.82, P < 0.01), and 36 months (0.80 vs. 0.77, P < 0.01). For NSCLC patients with MPE, the validated CAIL prognostic score integrates clinical characteristics and therapeutic modalities to predict survival.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with malignant pleural effusion (MPE) typically have poor prognoses, and predicting survival is challenging. The present study aimed to identify prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients with MPE in the time of immunotherapy and targeted therapy.
METHODS
METHODS
Data of 344 consecutive NSCLC patients with MPE on clinical, radiological, and molecular characteristics and treatment options were collected. The risk factors in the training cohort were assessed using univariate and multivariate proportional hazards analyses. A clinical prognostic score was established and validated.
RESULTS
RESULTS
According to the results of the multivariable survival analysis, the Eastern Cooperative Oncology Group (ECOG) performance score (PS), antiangiogenic therapy, immunotherapy, and lactic dehydrogenase (LDH) in pleural fluid (CAIL) prognostic score was developed (n = 275) and subsequently validated (n = 69). Patients who underwent risk stratification into low-, moderate-, and high-risk groups had median OS of 46.1, 23.1, and 9.6 months, respectively (P < 0.0001). The area under the curve (AUC) analysis showed the CAIL score to be superior at predicting survival compared with the LENT score at 6 (0.84 vs. 0.77, P < 0.01), 12 (0.87 vs. 0.82, P < 0.01), and 36 months (0.80 vs. 0.77, P < 0.01).
CONCLUSIONS
CONCLUSIONS
For NSCLC patients with MPE, the validated CAIL prognostic score integrates clinical characteristics and therapeutic modalities to predict survival.
Identifiants
pubmed: 37723659
doi: 10.1111/crj.13700
pmc: PMC10632079
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1158-1168Subventions
Organisme : National Natural Science Foundation of China
ID : 82072598
Organisme : National Natural Science Foundation of China
ID : 81871890
Organisme : National Natural Science Foundation of China
ID : 91859203
Organisme : 1-3-5 project for disciplines of excellence
Organisme : West China Hospital, Sichuan University, China
ID : ZYJC21052
Informations de copyright
© 2023 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.
Références
Lung Cancer. 2016 Sep;99:131-6
pubmed: 27565928
Medicine (Baltimore). 2016 Jun;95(26):e3996
pubmed: 27368006
Respiration. 2014;87(4):311-6
pubmed: 24457947
Invest New Drugs. 2020 Feb;38(1):211-218
pubmed: 31784866
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32895296
Thorac Cancer. 2016 Jan;7(1):136-9
pubmed: 26816548
Oncol Lett. 2020 Jan;19(1):449-459
pubmed: 31897158
Thorac Cancer. 2018 Feb;9(2):298-304
pubmed: 29297985
BMC Cancer. 2017 Aug 22;17(1):557
pubmed: 28830378
Transl Lung Cancer Res. 2021 Mar;10(3):1318-1326
pubmed: 33889512
Clin Transl Oncol. 2011 Jun;13(6):426-9
pubmed: 21680304
Ther Adv Med Oncol. 2020 Nov 05;12:1758835920970063
pubmed: 33224277
Cancer Chemother Pharmacol. 2013 Feb;71(2):457-61
pubmed: 23178954
Lancet Oncol. 2018 Jul;19(7):930-939
pubmed: 29908990
Lung. 2016 Feb;194(1):147-53
pubmed: 26678281
Int J Oncol. 2021 Mar;58(3):359-370
pubmed: 33650668
Thorax. 2014 Dec;69(12):1098-104
pubmed: 25100651
Mol Med Rep. 2018 Jun;17(6):8019-8030
pubmed: 29693703
Eur Respir J. 2018 Jul 27;52(1):
pubmed: 30054348
Lancet Respir Med. 2015 Jul;3(7):505-6
pubmed: 26170072
Thorac Cancer. 2019 Apr;10(4):815-822
pubmed: 30762312
Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849
pubmed: 30272503
Mol Clin Oncol. 2015 Mar;3(2):415-419
pubmed: 25798278
Clin Respir J. 2023 Nov;17(11):1158-1168
pubmed: 37723659
Med Oncol. 2013;30(3):676
pubmed: 23925664
Respirology. 2019 Dec;24(12):1198-1203
pubmed: 31209954
Eur J Intern Med. 2008 Jul;19(5):334-9
pubmed: 18549935
Oncologist. 2019 Feb;24(Suppl 1):S31-S41
pubmed: 30819829
JAMA Oncol. 2019 Mar 1;5(3):351-357
pubmed: 30605211
Chest. 2021 Sep;160(3):1075-1094
pubmed: 33852918
Transl Lung Cancer Res. 2015 Feb;4(1):36-54
pubmed: 25806345
Thorac Cancer. 2020 Feb;11(2):320-328
pubmed: 31837116